ImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

IBRX has been the topic of a number of other reports. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Trading Up 27.2 %

ImmunityBio stock opened at $3.04 on Thursday. The stock has a 50-day simple moving average of $3.78 and a 200 day simple moving average of $4.26. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53.

Institutional Trading of ImmunityBio

Several hedge funds have recently added to or reduced their stakes in IBRX. Captrust Financial Advisors acquired a new position in ImmunityBio in the 3rd quarter valued at $41,000. Algert Global LLC acquired a new position in shares of ImmunityBio in the second quarter valued at about $86,000. Virtu Financial LLC acquired a new position in shares of ImmunityBio in the third quarter valued at about $51,000. Dimensional Fund Advisors LP acquired a new stake in ImmunityBio in the 2nd quarter worth about $105,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in ImmunityBio in the 2nd quarter valued at about $126,000. 8.58% of the stock is owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.